Drug Repurposing & Design to inhibit the SARS-CoV2 proteases (CoV2-Anti-protease project)
- Funded by Institut Pasteur International Network (IPIN)
- Total publications:0 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Institut Pasteur International Network (IPIN)Research Location
N/ALead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Identification of antiviral molecules targeting SARS-CoV2 proteases. Structures of the proteases will be used to screen large chemical libraries in complement of the FDA approved drugs. High Througput Screening (HTS) using dual mCherry-Nanoluc reporter cell lines can screen thousands of compounds. Combined with virtual screening this allows coverage of a large chemical space including purchasable compounds libraries. The best hits will be further validated on SARS-CoV-2 growth assays. Validated hits will guide optimization of compounds.